Login Register Cart 0
Review Article

心力衰竭中的血管紧张素1型受体阻滞剂

卷 21, 期 2, 2020

页: [125 - 131] 页: 7

弟呕挨: 10.2174/1389450120666190821152000

价格: $65

摘要

肾素血管紧张素醛固酮系统（RAAS）的生理功能可维持心血管系统的稳态。在病理生理条件下，过度激活的RAAS会导致血管紧张素II（AngII）的浓度增加，以及过度激活的血管紧张素1型受体（AT1R），导致血管收缩，钠潴留和心肌细胞生长变化。它会引起心脏的心脏重塑，从而导致左心室肥大，扩张和功能障碍，最终导致心力衰竭（HF）。使用血管紧张素转化酶抑制剂（ACEi）或血管紧张素受体阻滞剂（ARB）抑制RAAS已显示可显着降低因HF引起的发病率和死亡率。与ARB相比，由于不适，ACEi已显示出较高的停药率。因此，ARB是与其他抗高血压药联合治疗HF的医生的首选。目前，有8种ARB已获得FDA批准并投入临床使用。即使它们与取代AngII的AT1R的同一位点结合，但临床结果却有显着差异。在这篇综述中，我们描述了每种ARB在治疗HF中的临床意义及其临床结果。

关键词: AT1R，AngII，血管紧张素受体阻滞剂，心力衰竭，心血管疾病，高血压，GPCR。

« Previous Next »
图形摘要

[1]
Hall JE. Control of blood pressure by the renin-angiotensin-aldosterone system. Clin Cardiol 1991; 14(8)(Suppl. 4): IV6-IV21.
[http://dx.doi.org/10.1002/clc.4960141802] [PMID: 1893644]
[2]
Yim HE, Yoo KH. Renin-Angiotensin system - considerations for hypertension and kidney. Electrolyte Blood Press 2008; 6(1): 42-50.
[http://dx.doi.org/10.5049/EBP.2008.6.1.42] [PMID: 24459521]
[3]
Carey RM, Siragy HM. Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation. Endocr Rev 2003; 24(3): 261-71.
[http://dx.doi.org/10.1210/er.2003-0001] [PMID: 12788798]
[4]
Streatfeild-James RM, Williamson D, Pike RN, Tewksbury D, Carrell RW, Coughlin PB. Angiotensinogen cleavage by renin: importance of a structurally constrained N-terminus. FEBS Lett 1998; 436(2): 267-70.
[http://dx.doi.org/10.1016/S0014-5793(98)01145-4] [PMID: 9781693]
[5]
Lu H, Cassis LA, Kooi CW, Daugherty A. Structure and functions of angiotensinogen. Hypertens Res 2016; 39(7): 492-500.
[http://dx.doi.org/10.1038/hr.2016.17] [PMID: 26888118]
[6]
Karnik SS, Unal H, Kemp JR, et al. International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli (corrected). Pharmacol Rev 2015; 67(4): 754-819.
[http://dx.doi.org/10.1124/pr.114.010454] [PMID: 26315714]
[7]
Karnik SS, Singh KD, Tirupula K, Unal H. Significance of angiotensin 1-7 coupling with MAS1 receptor and other GPCRs to the renin-angiotensin system: IUPHAR Review 22. Br J Pharmacol 2017; 174(9): 737-53.
[http://dx.doi.org/10.1111/bph.13742] [PMID: 28194766]
[8]
Wettschureck N, Offermanns S. Mammalian G proteins and their cell type specific functions. Physiol Rev 2005; 85(4): 1159-204.
[http://dx.doi.org/10.1152/physrev.00003.2005] [PMID: 16183910]
[9]
Manrique C, Lastra G, Gardner M, Sowers JR. The renin angiotensin aldosterone system in hypertension: roles of insulin resistance and oxidative stress. Med Clin North Am 2009; 93(3): 569-82.
[http://dx.doi.org/10.1016/j.mcna.2009.02.014] [PMID: 19427492]
[10]
Ainscough JF, Drinkhill MJ, Sedo A, et al. Angiotensin II type-1 receptor activation in the adult heart causes blood pressure-independent hypertrophy and cardiac dysfunction. Cardiovasc Res 2009; 81(3): 592-600.
[http://dx.doi.org/10.1093/cvr/cvn230] [PMID: 18703536]
[11]
Su Q, Huo CJ, Li HB, et al. Renin-angiotensin system acting on reactive oxygen species in paraventricular nucleus induces sympathetic activation via AT1R/PKCγ/Rac1 pathway in salt-induced hypertension. Sci Rep 2017; 7: 43107.
[http://dx.doi.org/10.1038/srep43107] [PMID: 28338001]
[12]
Ramchandran R, Takezako T, Saad Y, et al. Angiotensinergic stimulation of vascular endothelium in mice causes hypotension, bradycardia, and attenuated angiotensin response. Proc Natl Acad Sci USA 2006; 103(50): 19087-92.
[http://dx.doi.org/10.1073/pnas.0602715103] [PMID: 17148616]
[13]
Incalza MA, D’Oria R, Natalicchio A, Perrini S, Laviola L, Giorgino F. Oxidative stress and reactive oxygen species in endothelial dysfunction associated with cardiovascular and metabolic diseases. Vascul Pharmacol 2018; 100: 1-19.
[http://dx.doi.org/10.1016/j.vph.2017.05.005] [PMID: 28579545]
[14]
Ogita H, Liao J. Endothelial function and oxidative stress. Endothelium 2004; 11(2): 123-32.
[http://dx.doi.org/10.1080/10623320490482664] [PMID: 15370071]
[15]
Peach MJ, Cline WH Jr, Watts DT. Release of adrenal catecholamines by angiotensin. II. Circ Res 1966; 19(3): 571-5.
[http://dx.doi.org/10.1161/01.RES.19.3.571] [PMID: 4288687]
[16]
Parish RC, Miller LJ. Adverse effects of angiotensin converting enzyme (ACE) inhibitors. An update. Drug Saf 1992; 7(1): 14-31.
[http://dx.doi.org/10.2165/00002018-199207010-00004] [PMID: 1536695]
[17]
Gavras H, Gavras I. Angiotensin converting enzyme inhibitors. Properties and side effects. Hypertension 1988; 11(3 Pt 2): II37-41.
[http://dx.doi.org/10.1161/01.HYP.11.3_Pt_2.II37] [PMID: 3280490]
[18]
Zhang H, Unal H, Gati C, et al. Structure of the Angiotensin receptor revealed by serial femtosecond crystallography. Cell 2015; 161(4): 833-44.
[http://dx.doi.org/10.1016/j.cell.2015.04.011] [PMID: 25913193]
[19]
Zhang H, Unal H, Desnoyer R, et al. Structural basis for ligand recognition and functional selectivity at angiotensin receptor. J Biol Chem 2015; 290(49): 29127-39.
[http://dx.doi.org/10.1074/jbc.M115.689000] [PMID: 26420482]
[20]
Singh KD, Unal H, Desnoyer R, Karnik SS. Divergent spatiotemporal interaction of angiotensin receptor blocking drugs with angiotensin type 1 receptor. J Chem Inf Model 2018; 58(1): 182-93.
[http://dx.doi.org/10.1021/acs.jcim.7b00424] [PMID: 29195045]
[21]
Wingler LM, McMahon C, Staus DP, Lefkowitz RJ, Kruse AC. distinctive activation mechanism for angiotensin receptor revealed by a synthetic nanobody. Cell 2019; 176: 479-90. e12
[http://dx.doi.org/10.1016/j.cell.2018.12.006]
[22]
Singh KD, Unal H, Desnoyer R, Karnik SS. Mechanism of hormone peptide activation of a GPCR: Angiotensin II activated state of AT1R initiated by van der waals attraction. J Chem Inf Model 2019; 59(1): 373-85.
[http://dx.doi.org/10.1021/acs.jcim.8b00583] [PMID: 30608150]
[23]
Wong PC, Price WA Jr, Chiu AT, et al. Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174: an active metabolite of DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther 1990; 255(1): 211-7.
[PMID: 2213556]
[24]
Arumugam S, Sreedhar R, Thandavarayan RA, et al. Angiotensin receptor blockers: Focus on cardiac and renal injury. Trends Cardiovasc Med 2016; 26(3): 221-8.
[http://dx.doi.org/10.1016/j.tcm.2015.06.004] [PMID: 26169314]
[25]
Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355(9215): 1582-7.
[http://dx.doi.org/10.1016/S0140-6736(00)02213-3] [PMID: 10821361]
[26]
Svanström H, Pasternak B, Hviid A. Association of treatment with losartan vs candesartan and mortality among patients with heart failure. JAMA 2012; 307(14): 1506-12.
[http://dx.doi.org/10.1001/jama.2012.452] [PMID: 22496265]
[27]
Crozier I, Ikram H, Awan N, et al. Losartan hemodynamic study group. Losartan in heart failure. Hemodynamic effects and tolerability. Circulation 1995; 91(3): 691-7.
[http://dx.doi.org/10.1161/01.CIR.91.3.691] [PMID: 7828295]
[28]
Lam S. Azilsartan: a newly approved angiotensin II receptor blocker. Cardiol Rev 2011; 19(6): 300-4.
[http://dx.doi.org/10.1097/CRD.0b013e31822e9ba3] [PMID: 21983318]
[29]
White WB, Weber MA, Sica D, et al. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension 2011; 57(3): 413-20.
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.110.163402] [PMID: 21282560]
[30]
Sakamoto M, Asakura M, Nakano A, et al. Azilsartan, but not candesartan improves left ventricular diastolic function in patients with hypertension and heart failure. Int J Gerontol 2015; 9: 201-5.
[http://dx.doi.org/10.1016/j.ijge.2015.06.003]
[31]
Nakamura Y, Suzuki S, Saitoh S, Takeishi Y. New angiotensin II type 1 receptor blocker, azilsartan, attenuates cardiac remodeling after myocardial infarction. Biol Pharm Bull 2013; 36(8): 1326-31.
[http://dx.doi.org/10.1248/bpb.b13-00194] [PMID: 23727946]
[32]
White WB, Cuadra RH, Lloyd E, Bakris GL, Kupfer S. Effects of azilsartan medoxomil compared with olmesartan and valsartan on ambulatory and clinic blood pressure in patients with type 2 diabetes and prediabetes. J Hypertens 2016; 34(4): 788-97.
[http://dx.doi.org/10.1097/HJH.0000000000000839] [PMID: 26766564]
[33]
Georgiopoulos G, Katsi V, Oikonomou D, et al. Azilsartan as a potent antihypertensive drug with possible pleiotropic cardiometabolic effects: A review study. Front Pharmacol 2016; 7: 235.
[http://dx.doi.org/10.3389/fphar.2016.00235] [PMID: 27536242]
[34]
Takagi H, Mizuno Y, Niwa M, Goto SN, Umemoto T. A meta-analysis of randomized controlled trials of azilsartan therapy for blood pressure reduction. Hypertens Res 2014; 37(5): 432-7.
[http://dx.doi.org/10.1038/hr.2013.142] [PMID: 24108238]
[35]
Young JB, Dunlap ME, Pfeffer MA, et al. Candesartan in heart failure assessment of reduction in mortality and morbidity (charm) investigators and committees. mortality and morbidity reduction with candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the charm low-left ventricular ejection fraction trials. Circulation 2004; 110(17): 2618-26.
[http://dx.doi.org/10.1161/01.CIR.0000146819.43235.A9] [PMID: 15492298]
[36]
Yusuf S, Pfeffer MA, Swedberg K, et al. Charm investigators and committees. effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the charm-preserved trial. Lancet 2003; 362(9386): 777-81.
[http://dx.doi.org/10.1016/S0140-6736(03)14285-7] [PMID: 13678871]
[37]
Granger CB, McMurray JJ, Yusuf S, et al. CHARM investigators and committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003; 362(9386): 772-6.
[http://dx.doi.org/10.1016/S0140-6736(03)14284-5] [PMID: 13678870]
[38]
Pitt B. Candesartan reduced mortality and hospital admissions in chronic heart failure. ACP J Club 2004; 140(2): 32-3.
[http://dx.doi.org/10.1136/ebm.9.2.44] [PMID: 15122853]
[39]
Ripley TL, Chonlahan JS, Germany RE. Candesartan in heart failure. Clin Interv Aging 2006; 1(4): 357-66.
[http://dx.doi.org/10.2147/ciia.2006.1.4.357] [PMID: 18046913]
[40]
Lund LH. Heart failure with mid-range ejection fraction: Lessons from CHARM. Card Fail Rev 2018; 4(2): 70-2.
[http://dx.doi.org/10.15420/cfr.2018.11.2] [PMID: 30206479]
[41]
Ohlstein EH, Brooks DP, Feuerstein GZ, Ruffolo RR Jr. Inhibition of sympathetic outflow by the angiotensin II receptor antagonist, eprosartan, but not by losartan, valsartan or irbesartan: relationship to differences in prejunctional angiotensin II receptor blockade. Pharmacology 1997; 55(5): 244-51.
[http://dx.doi.org/10.1159/000139534] [PMID: 9399334]
[42]
Brodsky S, Gurbanov K, Abassi Z, et al. Effects of eprosartan on renal function and cardiac hypertrophy in rats with experimental heart failure. Hypertension 1998; 32(4): 746-52.
[http://dx.doi.org/10.1161/01.HYP.32.4.746] [PMID: 9774374]
[43]
Hollenberg NK. Potential of the angiotensin II receptor 1 blocker eprosartan in the management of patients with hypertension or heart failure. Curr Hypertens Rep 2001; 3(Suppl. 1): S25-8.
[http://dx.doi.org/10.1007/s11906-001-0068-9] [PMID: 11580885]
[44]
Barone FC, Coatney RW, Chandra S, et al. Eprosartan reduces cardiac hypertrophy, protects heart and kidney, and prevents early mortality in severely hypertensive stroke-prone rats. Cardiovasc Res 2001; 50(3): 525-37.
[http://dx.doi.org/10.1016/S0008-6363(01)00257-7] [PMID: 11376628]
[45]
Behr TM, Willette RN, Coatney RW, et al. Eprosartan improves cardiac performance, reduces cardiac hypertrophy and mortality and downregulates myocardial monocyte chemoattractant protein-1 and inflammation in hypertensive heart disease. J Hypertens 2004; 22(3): 583-92.
[http://dx.doi.org/10.1097/00004872-200403000-00022] [PMID: 15076165]
[46]
Suzuki G, Mishima T, Tanhehco EJ, et al. Effects of the AT1-receptor antagonist eprosartan on the progression of left ventricular dysfunction in dogs with heart failure. Br J Pharmacol 2003; 138(2): 301-9.
[http://dx.doi.org/10.1038/sj.bjp.0705032] [PMID: 12540520]
[47]
Massie BM, Carson PE, McMurray JJ, et al. I-PRESERVE Investigators. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008; 359(23): 2456-67.
[http://dx.doi.org/10.1056/NEJMoa0805450] [PMID: 19001508]
[48]
Rector TS, Carson PE, Anand IS, et al. I-PRESERVE Trial Investigators. Assessment of long-term effects of irbesartan on heart failure with preserved ejection fraction as measured by the minnesota living with heart failure questionnaire in the irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial. Circ Heart Fail 2012; 5(2): 217-25.
[http://dx.doi.org/10.1161/CIRCHEARTFAILURE.111.964221] [PMID: 22267751]
[49]
Abraham HM, White CM, White WB. The comparative efficacy and safety of the angiotensin receptor blockers in the management of hypertension and other cardiovascular diseases. Drug Saf 2015; 38(1): 33-54.
[http://dx.doi.org/10.1007/s40264-014-0239-7] [PMID: 25416320]
[50]
Watanabe R, Suzuki J, Wakayama K, et al. Angiotensin II receptor blocker irbesartan attenuates cardiac dysfunction induced by myocardial infarction in the presence of renal failure. Hypertens Res 2016; 39(4): 237-44.
[http://dx.doi.org/10.1038/hr.2015.141] [PMID: 26657004]
[51]
Zhang F, Zhou G, Guo L, Lu F, Zhou G. Comparison of clinical efficacy of metoprolol combined with irbesartan and hydrochlorothiazide and non-invasive ventilator in the emergency treatment of patients with severe heart failure. Exp Ther Med 2018; 16(6): 5059-66.
[PMID: 30542460]
[52]
Utsumi K, Yasuda F, Watanabe Y, et al. Effects of olmesartan and imidapril on the plasma adiponectin, P-selectin, and MDA-LDL levels of diabetic nephropathy patients. Clin Chim Acta 2012; 413(1-2): 348-9.
[http://dx.doi.org/10.1016/j.cca.2011.09.024] [PMID: 21983097]
[53]
Miura M, Sakata Y, Miyata S, et al. SUPPORT Trial Investigators. Influence of Left Ventricular Ejection Fraction on the Effects of Supplemental Use of Angiotensin Receptor Blocker Olmesartan in Hypertensive Patients With Heart Failure. Circ J 2016; 80(10): 2155-64.
[http://dx.doi.org/10.1253/circj.CJ-16-0577] [PMID: 27628221]
[54]
Sakata Y, Shiba N, Takahashi J, et al. SUPPORT Trial Investigators. Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure: the supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial. Eur Heart J 2015; 36(15): 915-23.
[http://dx.doi.org/10.1093/eurheartj/ehu504] [PMID: 25637937]
[55]
Sukumaran V, Veeraveedu PT, Gurusamy N, et al. Olmesartan attenuates the development of heart failure after experimental autoimmune myocarditis in rats through the modulation of ANG 1-7 mas receptor. Mol Cell Endocrinol 2012; 351(2): 208-19.
[http://dx.doi.org/10.1016/j.mce.2011.12.010] [PMID: 22200414]
[56]
Sukumaran V, Watanabe K, Veeraveedu PT, et al. Olmesartan, an AT1 antagonist, attenuates oxidative stress, endoplasmic reticulum stress and cardiac inflammatory mediators in rats with heart failure induced by experimental autoimmune myocarditis. Int J Biol Sci 2011; 7(2): 154-67.
[http://dx.doi.org/10.7150/ijbs.7.154] [PMID: 21383952]
[57]
Hirohata A, Yamamoto K, Miyoshi T, et al. Four-year clinical outcomes of the OLIVUS-Ex (impact of Olmesartan on progression of coronary atherosclerosis: evaluation by intravascular ultrasound) extension trial. Atherosclerosis 2012; 220(1): 134-8.
[http://dx.doi.org/10.1016/j.atherosclerosis.2011.10.013] [PMID: 22119063]
[58]
Padwal R, Lin M, Etminan M, Eurich DT. Comparative effectiveness of olmesartan and other angiotensin receptor blockers in diabetes mellitus: retrospective cohort study. Hypertension 2014; 63(5): 977-83.
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.113.02855] [PMID: 24535009]
[59]
Wang Y, Qiao S, Han DW, et al. Telmisartan Improves Insulin Resistance: A Meta-Analysis. Am J Ther 2018; 25(6): e642-51.
[http://dx.doi.org/10.1097/MJT.0000000000000733] [PMID: 29557807]
[60]
Suksomboon N, Poolsup N, Prasit T. Systematic review of the effect of telmisartan on insulin sensitivity in hypertensive patients with insulin resistance or diabetes. J Clin Pharm Ther 2012; 37(3): 319-27.
[http://dx.doi.org/10.1111/j.1365-2710.2011.01295.x] [PMID: 21848583]
[61]
Verdecchia P, Angeli F, Gentile G, Mazzotta G, Reboldi G. Telmisartan for the reduction of cardiovascular morbidity and mortality. Expert Rev Clin Pharmacol 2011; 4(2): 151-61.
[http://dx.doi.org/10.1586/ecp.10.141] [PMID: 22115399]
[62]
Vidt DG. Telmisartan, ramipril, or both in patients at high risk for vascular events. Curr Hypertens Rep 2008; 10(5): 343-4.
[http://dx.doi.org/10.1007/s11906-008-0064-4] [PMID: 18775108]
[63]
Cice G, Di Benedetto A, D’Isa S, et al. Effects of telmisartan added to Angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure a double-blind, placebo-controlled trial. J Am Coll Cardiol 2010; 56(21): 1701-8.
[http://dx.doi.org/10.1016/j.jacc.2010.03.105] [PMID: 21070920]
[64]
Yusuf S, Teo K, Anderson C, et al. Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008; 372(9644): 1174-83.
[http://dx.doi.org/10.1016/S0140-6736(08)61242-8] [PMID: 18757085]
[65]
Foulquier S, Böhm M, Schmieder R, et al. Impact of telmisartan on cardiovascular outcome in hypertensive patients at high risk: a Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease subanalysis. J Hypertens 2014; 32(6): 1334-41.
[http://dx.doi.org/10.1097/HJH.0000000000000154] [PMID: 24621807]
[66]
Sukumaran V, Watanabe K, Veeraveedu PT, et al. Telmisartan, an angiotensin-II receptor blocker ameliorates cardiac remodeling in rats with dilated cardiomyopathy. Hypertens Res 2010; 33(7): 695-702.
[http://dx.doi.org/10.1038/hr.2010.67] [PMID: 20535115]
[67]
Jianghua Z, Shijuan L, Moshui C, et al. The effects of telmisartan on serum level of copeptin in patients with chronic heart failure. Heart 2012; 98(Suppl. 2): E1-E319.
[http://dx.doi.org/10.1136/heartjnl-2012-302920v.10]
[68]
Lin S, Shi Y, Wei Q, et al. Effects of telmisartan on serum adiponectin and left ventricular remodeling in patients with essential hypertension. Biomed Res 2018; 29(7): 1455-8.
[69]
Hou Y, Zhang F, Liu Z, Su S, Wu X, Wang Z. Effect of telmisartan and enalapril on ventricular remodeling and kidney prognosis of patients with coronary artery disease complicated with diabetic nephropathy. Exp Ther Med 2017; 13(1): 131-4.
[http://dx.doi.org/10.3892/etm.2016.3933] [PMID: 28123481]
[70]
Tang L, Yi R, Yang B, Li H, Chen H, Liu Z. Valsartan inhibited HIF-1α pathway and attenuated renal interstitial fibrosis in streptozotocin-diabetic rats. Diabetes Res Clin Pract 2012; 97(1): 125-31.
[http://dx.doi.org/10.1016/j.diabres.2012.01.037] [PMID: 22377232]
[71]
Cohn JN, Tognoni G. Valsartan heart failure trial investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345(23): 1667-75.
[http://dx.doi.org/10.1056/NEJMoa010713] [PMID: 11759645]
[72]
Carson P, Tognoni G, Cohn JN. Effect of Valsartan on hospitalization: results from Val-HeFT. J Card Fail 2003; 9(3): 164-71.
[http://dx.doi.org/10.1054/jcaf.2003.22] [PMID: 12815565]
[73]
Webb RL, de Gasparo M. Role of the angiotensin II receptor blocker valsartan in heart failure. Exp Clin Cardiol 2001; 6(4): 215-21.
[PMID: 20428262]
[74]
Pfeffer MA, McMurray J, Leizorovicz A, et al. Valsartan in acute myocardial infarction trial (VALIANT): rationale and design. Am Heart J 2000; 140(5): 727-50.
[http://dx.doi.org/10.1067/mhj.2000.108832] [PMID: 11054617]
[75]
Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan in acute myocardial infarction trial investigators. valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349(20): 1893-906.
[http://dx.doi.org/10.1056/NEJMoa032292] [PMID: 14610160]
[76]
Kaplinsky E. Sacubitril/valsartan in heart failure: latest evidence and place in therapy. Ther Adv Chronic Dis 2016; 7(6): 278-90.
[http://dx.doi.org/10.1177/2040622316665350] [PMID: 27803793]
[77]
Silva-Cardoso J, Brás D, Canário-Almeida F, et al. Neurohormonal modulation: The new paradigm of pharmacological treatment of heart failure. Rev Port Cardiol 2019; 38(3): 175-85.
[http://dx.doi.org/10.1016/j.repc.2018.10.011] [PMID: 31029493]
[78]
Bangalore S, Fakheri R, Toklu B, Ogedegbe G, Weintraub H, Messerli FH. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in patients without heart failure? insights from 254,301 patients from randomized trials. Mayo Clin Proc 2016; 91(1): 51-60.
[http://dx.doi.org/10.1016/j.mayocp.2015.10.019] [PMID: 26763511]
[79]
Turnbull F, Neal B, Pfeffer M, et al. Blood Pressure Lowering Treatment Trialists’ Collaboration. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens 2007; 25(5): 951-8.
[http://dx.doi.org/10.1097/HJH.0b013e3280bad9b4] [PMID: 17414657]
[80]
Lindholm LH, Carlberg B. The new Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2014): a giant undertaking. Hypertens Res 2014; 37: 391-2.
[81]
Guidelines for secondary prevention of myocardial infarction. Circ J 2011; 77: 231-48.

Rights & Permissions Print Cite
Article Metrics
32
3
© 2024 Bentham Science Publishers | Privacy Policy